×
Back to Agenda
S21 : Toward Tomorrow’s Norm: Patient-Driven Drug Development through Collaboration with Academia and Emerging Biopharma
Session Chair(s)
Junko Sato, PHD
Associate Executive Director, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Speaker(s)
Midori Senoo
Managing Director, Myotonic Dystrophy Patients' Group of Japan, Japan
Harumasa Nakamura, MD, PHD
Director of Department of Clinical Research Support, , National Center of Neurology and Psychiatry, Japan
Haruhiko Morita
President and Chief Executive Officer (CEO), Modalis Therapeutics Corporation, Japan
Michiyo Ohshima, MBA
Senior Director, Head of Japan Portfolio and Project Management, Pfizer R&D GK, Japan
Have an account?